Abstract
Previously, we showed that serum soluble interleukin-2 receptor (sIL-2R) levels, a marker for T-cell activation, were higher in complex regional pain syndrome (CRPS) patients than in healthy controls, suggesting pathogenic T-cell activation in CRPS. Additionally, sIL-2R levels discriminated well between CRPS and healthy controls with a high sensitivity (90%) and specificity (89.5%), suggesting a possible role for sIL-2R in the diagnosis of CRPS. In order to further validate this marker in the diagnostic workup of CRPS, we conducted this prospective cohort study in which we determined sIL-2R levels in patients that were referred to our tertiary referral center with a suspicion of CRPS in a limb, and subsequently compared sIL-2R levels between the patients that were diagnosed with CRPS (CRPS group) and those who were not (no CRPS group). A group of anonymous blood bank donors were used as a healthy control group. Furthermore, we explored the relationship between sIL-2R and CRPS disease severity using the CRPS severity score. Median sIL-2R levels of both the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and no CRPS group (3654.0 pg/ml; Q3-Q1: 4429.0-2095.5) were significantly higher than that of the control group (1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): CRPS vs. controls, p < .001; no CRPS vs. controls, p < 0.001. Serum sIL-2R levels did not differ significantly between the CRPS and no CRPS group. A statistically significant negative correlation was observed between sIL-2R levels and the CRPS severity score (rs = −0.468, p = 0.024). Our results confirm our previous findings of higher sIL-2R levels in CRPS patients than in healthy controls. We further showed that serum sIL-2R cannot differentiate between CRPS and other pain conditions of a limb in a tertiary referral setting. Interestingly, a negative correlation was found between sIL-2R and CRPS disease severity; this finding warrants further research into the relationship between sIL-2R and CRPS disease severity.
Highlights
Complex regional pain syndrome (CRPS) is characterized by continuous pain which is accompanied by various sensory, motor, vasomotor, sudomotor, and trophic disturbances [1]
Based on the findings from our previous study in which soluble interleukin-2 receptor (sIL-2R) levels were found to be significantly higher in CRPS patients than in healthy controls [8], we conducted this current study in which we investigated whether serum sIL-2R could be used to help establish the diagnosis CRPS in patients who were referred to a tertiary referral center with pain in a limb that was suspected to be caused by CRPS
We conclude that serum sIL-2R cannot be used in a tertiary referral setting to differentiate CRPS from other pain conditions of a limb in patients referred with a suspicion of CRPS
Summary
Complex regional pain syndrome (CRPS) is characterized by continuous pain which is accompanied by various sensory, motor, vasomotor, sudomotor, and trophic disturbances [1]. The onset of CRPS is preceded by damage to the tissues of a limb, for example, due to fracture or surgery [2]. If CRPS is left untreated, it can have incapacitating consequences on the function of the affected limb, and on the social life of patients [3]. Appropriate treatment is often initiated too late due to a delay in diagnosis [4]. This diagnostic delay is mostly due to two reasons. The (early) diagnosis of CRPS cannot yet be established by objective diagnostic testing. The pathophysiology of CRPS is complex and still incompletely understood; this lack
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.